leisure time -WSS

leisure time

author：hotspot 2025-09-02 05:50:13 - browse：97

Are there still too many biotech companies? How do you know when you’re in a bubble? And is there a wrong way to pronounce “TIGIT”?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.

For more on what we cover, here’s the news from Biogen; here’s more on Illumina; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

WSS

Beware the threat of staffing cuts at the CDC

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Baltimore teen accused of firing into crowd during block party mass shooting

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Commercial surrogacy can be ethical, despite pope’s claims

Ukraine taking heavy casualties 10 weeks into its counteroffensive

hotspot

leisure time

entertainment

Hepatitis C has a cure — but many Americans still lack access to it

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

At least 13 dead in Texas as scorching temps continue

Cybersecurity threat forces Lurie Children's to take systems offline

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Continuity nursing helped my family in our darkest PICU moments

Juul spent big to court Black leaders to promote its e

Hepatitis C has a cure — but many Americans still lack access to it

Medicare drug price negotiation’s day in court

focus

New Ultima Genomics DNA sequencer can read genome for $100

Listen: Racing for gene therapy & a pioneering approval

Time to name cancers by genetics, not organ of origin, expert says

A $475,000 price tag for a new cancer drug: crazy or meh?

Clinical trials must include more disabled people

Cognito secures funding to test medical device for Alzheimer's

hotspot

entertainment

focus

explore